📰 Full Story
On Super Bowl LX (Feb. 9, 2026) tennis great Serena Williams starred in a high‑profile commercial for telehealth company Ro promoting GLP‑1 weight‑loss medication, drawing swift public backlash.
The spot showed Williams administering an injectable and using Ro’s app to order a new pill formulation, and she said she lost about 34 pounds (roughly 15 kg) over a year and experienced improved knee stress, blood sugar and cholesterol.
Ro and Williams disclosed that her husband, Alexis Ohanian, is an investor and board member of Ro.
Critics on social media and in commentary called the ad inappropriate for a mass, family‑viewed event and questioned the message from a former elite athlete.
The ad was part of a broader Super Bowl advertising push by makers and sellers of GLP‑1 drugs and related telehealth services; Reuters reported industry players including Novo Nordisk, Eli Lilly and direct‑to‑consumer firms spent heavily on spots as pill versions of GLP‑1s launch and companies vie for market share.
The ads come amid rising consumer demand, pricing pressure and regulatory scrutiny of weight‑loss medications.
🔗 Based On
🕰️ The Story So Far: An Evolving Timeline
02/09/2026, 15:53:16
Serena Williams criticised for GLP-1 Super Bowl ad
01/29/2026, 05:23:48
Serena Williams fronts Super Bowl GLP-1 ad










:max_bytes(150000):strip_icc():focal(834x260:836x262)/christina-applegate-060425-b649d2a0561645f7b40462e53dda8c55.jpg)











💬 Commentary